Hero Background

Zika Virus Testing Market

ID: MRFR/LS/4207-HCR
100 Pages
Rahul Gotadki
Last Updated: April 24, 2026
Zika Virus Testing Market Research Report Information By Tests Include (serological/Zika virus antibody and molecular/nucleic acid amplification), End-Users (Diagnostic units, hospitals, pathology labs), Regions (Asia Pacific, Europe, Americas, and the Middle East and Africa) Forecast till 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Test Type (USD Billion)
      1. 4.1.1 Serological/Zika virus antibody
      2. 4.1.2 Molecular/Nucleic acid amplification
    2. 4.2 Healthcare, BY End-User (USD Billion)
      1. 4.2.1 Diagnostic units
      2. 4.2.2 Hospitals
      3. 4.2.3 Pathology labs
    3. 4.3 Healthcare, BY Region (USD Billion)
      1. 4.3.1 North America
        1. 4.3.1.1 US
        2. 4.3.1.2 Canada
      2. 4.3.2 Europe
        1. 4.3.2.1 Germany
        2. 4.3.2.2 UK
        3. 4.3.2.3 France
        4. 4.3.2.4 Russia
        5. 4.3.2.5 Italy
        6. 4.3.2.6 Spain
        7. 4.3.2.7 Rest of Europe
      3. 4.3.3 APAC
        1. 4.3.3.1 China
        2. 4.3.3.2 India
        3. 4.3.3.3 Japan
        4. 4.3.3.4 South Korea
        5. 4.3.3.5 Malaysia
        6. 4.3.3.6 Thailand
        7. 4.3.3.7 Indonesia
        8. 4.3.3.8 Rest of APAC
      4. 4.3.4 South America
        1. 4.3.4.1 Brazil
        2. 4.3.4.2 Mexico
        3. 4.3.4.3 Argentina
        4. 4.3.4.4 Rest of South America
      5. 4.3.5 MEA
        1. 4.3.5.1 GCC Countries
        2. 4.3.5.2 South Africa
        3. 4.3.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Abbott Laboratories (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche Diagnostics (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Thermo Fisher Scientific (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Siemens Healthineers (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bio-Rad Laboratories (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Cepheid (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Hologic (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Quidel Corporation (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TEST TYPE
    4. 6.4 US MARKET ANALYSIS BY END-USER
    5. 6.5 CANADA MARKET ANALYSIS BY TEST TYPE
    6. 6.6 CANADA MARKET ANALYSIS BY END-USER
    7. 6.7 EUROPE MARKET ANALYSIS
    8. 6.8 GERMANY MARKET ANALYSIS BY TEST TYPE
    9. 6.9 GERMANY MARKET ANALYSIS BY END-USER
    10. 6.10 UK MARKET ANALYSIS BY TEST TYPE
    11. 6.11 UK MARKET ANALYSIS BY END-USER
    12. 6.12 FRANCE MARKET ANALYSIS BY TEST TYPE
    13. 6.13 FRANCE MARKET ANALYSIS BY END-USER
    14. 6.14 RUSSIA MARKET ANALYSIS BY TEST TYPE
    15. 6.15 RUSSIA MARKET ANALYSIS BY END-USER
    16. 6.16 ITALY MARKET ANALYSIS BY TEST TYPE
    17. 6.17 ITALY MARKET ANALYSIS BY END-USER
    18. 6.18 SPAIN MARKET ANALYSIS BY TEST TYPE
    19. 6.19 SPAIN MARKET ANALYSIS BY END-USER
    20. 6.20 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
    21. 6.21 REST OF EUROPE MARKET ANALYSIS BY END-USER
    22. 6.22 APAC MARKET ANALYSIS
    23. 6.23 CHINA MARKET ANALYSIS BY TEST TYPE
    24. 6.24 CHINA MARKET ANALYSIS BY END-USER
    25. 6.25 INDIA MARKET ANALYSIS BY TEST TYPE
    26. 6.26 INDIA MARKET ANALYSIS BY END-USER
    27. 6.27 JAPAN MARKET ANALYSIS BY TEST TYPE
    28. 6.28 JAPAN MARKET ANALYSIS BY END-USER
    29. 6.29 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
    30. 6.30 SOUTH KOREA MARKET ANALYSIS BY END-USER
    31. 6.31 MALAYSIA MARKET ANALYSIS BY TEST TYPE
    32. 6.32 MALAYSIA MARKET ANALYSIS BY END-USER
    33. 6.33 THAILAND MARKET ANALYSIS BY TEST TYPE
    34. 6.34 THAILAND MARKET ANALYSIS BY END-USER
    35. 6.35 INDONESIA MARKET ANALYSIS BY TEST TYPE
    36. 6.36 INDONESIA MARKET ANALYSIS BY END-USER
    37. 6.37 REST OF APAC MARKET ANALYSIS BY TEST TYPE
    38. 6.38 REST OF APAC MARKET ANALYSIS BY END-USER
    39. 6.39 SOUTH AMERICA MARKET ANALYSIS
    40. 6.40 BRAZIL MARKET ANALYSIS BY TEST TYPE
    41. 6.41 BRAZIL MARKET ANALYSIS BY END-USER
    42. 6.42 MEXICO MARKET ANALYSIS BY TEST TYPE
    43. 6.43 MEXICO MARKET ANALYSIS BY END-USER
    44. 6.44 ARGENTINA MARKET ANALYSIS BY TEST TYPE
    45. 6.45 ARGENTINA MARKET ANALYSIS BY END-USER
    46. 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
    47. 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
    48. 6.48 MEA MARKET ANALYSIS
    49. 6.49 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
    50. 6.50 GCC COUNTRIES MARKET ANALYSIS BY END-USER
    51. 6.51 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
    52. 6.52 SOUTH AFRICA MARKET ANALYSIS BY END-USER
    53. 6.53 REST OF MEA MARKET ANALYSIS BY TEST TYPE
    54. 6.54 REST OF MEA MARKET ANALYSIS BY END-USER
    55. 6.55 KEY BUYING CRITERIA OF HEALTHCARE
    56. 6.56 RESEARCH PROCESS OF MRFR
    57. 6.57 DRO ANALYSIS OF HEALTHCARE
    58. 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    59. 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    60. 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
    61. 6.61 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
    62. 6.62 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
    63. 6.63 HEALTHCARE, BY END-USER, 2024 (% SHARE)
    64. 6.64 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
    65. 6.65 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY END-USER, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY END-USER, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY END-USER, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY END-USER, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY END-USER, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY END-USER, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY END-USER, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY END-USER, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY END-USER, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY END-USER, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY END-USER, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY END-USER, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY END-USER, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY END-USER, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY END-USER, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY END-USER, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY END-USER, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY END-USER, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY END-USER, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY END-USER, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY END-USER, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY END-USER, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY END-USER, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY END-USER, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY END-USER, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY END-USER, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY END-USER, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY END-USER, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY END-USER, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Test Type (USD Billion, 2025-2035)

  • Serological/Zika virus antibody
  • Molecular/Nucleic acid amplification

Healthcare By End-User (USD Billion, 2025-2035)

  • Diagnostic units
  • Hospitals
  • Pathology labs